Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

NatHis-SMA is a prospective, longitudinal and interventional study of the natural history of patients with type 2 and 3 Spinal Muscular Atrophy (SMA). The purpose of this study is to characterize the disease course over 2 years and identify prognostic variables of the disease and biomarkers of SMA progression, as well as determine the best outcome measures for further therapeutics approaches.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study

NCT05839145

Muscular Atrophy, Spinal, Type II Muscular Atrophy, Spinal, Type III

NOT_YET_RECRUITING NA

Long Term Trajectories of SMA Patients Receiving or Not Disease-modifying Treatments

NCT05768048

Spinal Muscular Atrophy

RECRUITING

Natural History of SMA

NCT05755451

Muscular Atrophy, Spinal

RECRUITING

Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.

NCT02044029

Healthy Volunteer, Muscular Atrophy, Spinal

COMPLETED

MAP THE SMA: a Machine-learning Based Algorithm to Predict THErapeutic Response in Spinal Muscular Atrophy

NCT05769465

Spinal Muscular Atrophy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Spinal Muscular Atrophy Type 3 Spinal Muscular Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Strength, function and activity measurements

Intervention Type OTHER

Muscle MRI

Intervention Type OTHER

Electrophysiology measurements

Intervention Type OTHER

Blood sampling for biomarker analysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 or 3 spinal muscular atrophy genetically confirmed
* Age superior or equal to 2 years old up to 30 years of age included
* For patients older than 6 years old, willing and able to comply with all protocol requirements and procedures.
* For non-ambulant patients, able to sit upright in a wheelchair for at least three hours
* Patients over 18 years of age and parent(s)/legal guardian(s) of patients \< 18 years of age must provide written informed consent prior to participating in the study and informed assent will be obtained from minors at least 7 years of age when required by regulation.
* In France only: Affiliated to or a beneficiary of a social security category

Exclusion Criteria

* Previously treated with an investigational drug within 6 months prior the recruitment in this study.
* Other condition which may significantly interfere with the assessment of the SMA and is clearly not related to the disease
* Current or anticipated participation in any therapeutic investigational clinical studies.
* Patients with specific contraindication to MRI (i.e. metallic foreign body, claustrophobia, and others deemed to be prohibitive by the investigators) will be allowed to participate, but MRI will not be performed.
* For women : pregnancy or current breastfeeding

Minimum Eligible Age

2 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No